Levothyroxine Sodium is the sodium salt of levothyroxine, a synthetic levoisomer of thyroxine (T4) that is similar to the endogenous hormone produced by the thyroid gland.
Market Analysis and Insights: Global Levothyroxine Sodium Market
Due to the COVID-19 pandemic, the global Levothyroxine Sodium market size is estimated to be worth US$ 3713.7 million in 2022 and is forecast to a readjusted size of US$ 4382.9 million by 2028 with a CAGR of 2.8% during the review period. Fully considering the economic change by this health crisis, Oral accounting for % of the Levothyroxine Sodium global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospitals segment is altered to an % CAGR throughout this forecast period.
Abbvie was the global greatest company in Levothyroxine Sodium industry, with the revenue market Share of 23% , followed by Mylan Pharma, Merck, Pfizer, Lannett Company, Novartis, Fresenius Kabi, IBSA, Piramal Critical Care, Abbott.North America is the largest Levothyroxine Sodium market with about 69% market share. Europe is follower, accounting for about 17% market share.
Global Levothyroxine Sodium Scope and Segment
Levothyroxine Sodium market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Levothyroxine Sodium market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Oral
Injection
Segment by Application
Hospitals
Pharmacy
Others
By Company
Abbvie
Mylan Pharma
Merck
Pfizer
Lannett Company
Novartis
Fresenius Kabi
IBSA
Piramal Critical Care
Abbott
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE